EGFR and skin squamous cell carcinoma: Currently, the only two approved therapies for cSCC are cetuximab, an anti-EGFR antibody that targets keratinocyte dysfunction, and cemiplimab, an anti-PD-1 antibody, that targets inappropriate immune interactions.